Leukodystrophy and bone marrow transplantation: Role of mixed hematopoietic chimerism

Neurochemical Research

Volumn 24, Issue 4, 1999, Pages 537-549

  Kaufman, Christina L ^a,b,c   Ildstad, Suzanne T ^a  

^a Institute for Cellular Therapeutics   (United States)

^b University of Louisville School of Medicine   (United States)

^c University of Louisville   (United States)

Author keywords

Bone marrow transplantation; Chimerism; Leukodystrophy

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ALEXANDER DISEASE; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; EXPERIMENTAL MODEL; FARBER DISEASE; GAUCHER DISEASE; GLOBOID CELL LEUKODYSTROPHY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; LEUKODYSTROPHY; LYSOSOME STORAGE DISEASE; MANNOSIDOSIS; MAROTEAUX LAMY SYNDROME; METACHROMATIC LEUKODYSTROPHY; MICROGLIA; MOTOR NEURON DISEASE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; PRIORITY JOURNAL; SANDHOFF DISEASE; TAY SACHS DISEASE; WHOLE BODY RADIATION;

EID: 0032917404     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022587914079     Document Type: Article

References (90)

1. Thomas, E.D., Lochte, H.L., Cannon, J.H., Sahler, D.D., and Free-bee, J.W. 1959. Supralethal whole body irradiation and isologous marrow transplantation in man. J. Clin. Invest. 38:1709.
2. Murphy, W.J., Reynolds, C.W., Tiberghien, P., and Longo, D.L. 1993. Natural killer cells and bone marrow transplantation. J. National Cancer Inst. 85:1475.
3. Down, J.D., Tarbell, N.J., Thames, H.D., and Mauch, P.M. 1991. Syngeneic and allogeneic bone marrow engraftraent after total body irradiation: Dependence on dose, dose rate, and fractionation. Blood 77:661.
4. Nilsson, S., Doone, M., Tiarks, C., Weier, H., Quesenberry, P.J. 1997. Potential and distribution of transplanted hematopoietic stem cell in a nonablated mouse model. Blood 89:4013.
5. Down, J.D., Boudewijn, A., Dillingh, J.H., Fox, B.W., and Ploemacher, R.E. 1994. Relationships between ablation of distinct haemopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs. British. J. Cancer 70:611.
6. Colson, Y.L., Wren, S.M., Schuchert, M.J., Patrene, K.D., Johnson, P.C., Boggs, S.S., and Ildstad, S.T. 1998. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J. Immunology 155:4179.
7. Exner, B.G., Colson, Y.L., Li, H., and Ildstad, S.T. 1997. In vivo depletion of host CD4+ and CD8+ cells permits engraftment of bone marrow stem cells and tolerance induction with minimal conditioning. Surgery 122:221.
8. Storb, R., Yu, C., Wagner, J.L., Deeg, H.J., Nash, R.A., Kiem, H.P., Leisenring W., and Shulman, H. 1997. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048.
9. Ildstad, S.T., Bluestone, J.A., and Sachs, D.H. 1986. Alloresistance to engraftment of allogeneic donor bone marrow is mediated by an LyT2+ T-cell in mixed allogeneic reconstitution (C57BL10/Sn + B10.D2/nSn->C57BL10/Sn). J. Exp. Med. 163: 1343.
10. Billingham, R.E. 1966. The biology of graft-versus host disease. Harvey Lectures 62:21.
11. Martin, P.J., Hansen, J.A., Storb R., and Thomas, E.D. 1987. Human marrow transplantation: An immunological perspective. Advances in Immunology 40:379.
12. Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R., Lerner, K.G., and Thomas, E.D. 1974. Clinical manifestations of graft-versus host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295.
13. Takata, M., Imai, T., and Hirone, T. 1993. Immunoelectronmicroscopy of acute graft versus host disease of the skin after allogeneic bone marrow transplantation. Journal of Clinical Pathology 46:801.
14. Truitt, R.L., and Atasoylu, A.A. 1991. Contribution of CD4 and CD8 T cells to graft versus host disease and graft bersus leukemia reactivity after transplantation of MHC compatible bone marrow. Bone Marrow Transplantation 8:51.
15. Blazar, B.R., Taylor, P.A., Panoskaltsis-Mortarim, A., Barrett, T.A., Bluestone, J.A., and Vallera, D.A. 1996. Lethal murine graft versus host disease induced by donor gamma delta expressing T cells with specificity for host non-classical major histocompatibility complex class Ib antigens. Blood 87:827.
16. Beatty, P.G., Kollman, C., and Howe, C.W. 1995. Unrelated-donor marrow transplants: the experience of the National Marrow Donor Program. Clinical Transplants 271:231.
17. Korngold, B., and Sprent, J. 1978. Lethal graft-versus host diesease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. Journal of Experimental Medicine 148:1687.
18. Yeager, A.M., Vogelsang, G.B., Jones, R.J., Farmer, E.R., Hess, A.D., and Santos, G.W. 1993. Cyclosporine induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. Leukemia & Lymphoma 11:215.
19. Appleton, A.L., Sviland, L., Wilkes, J., Pearson, A.D., and Malcolm, A.J. 1994. Late development of graft versus host disease in an autologous BMT recipient. Bone Marrow Transplantation 13: 823.
20. Armitage, J.O. 1994. Bone marrow transplantation. N. Eng. J. Med. 330:827.
21. Hansen, J.A., Anasetti, C., and Martin, P.J. 1994. The Seattle Experience, p. 193-209 in Terasaki, P.I., Checka, J.M. (eds.), Clinical Transplants, UCLA Tissue Typing Laboratory, Los Angeles.
22. Beatty, P.G., Clift, R., Mickelson, E.M., Nisperos, B., Slournoy, N., Martin, P.J., Sanders, J.E., Stewart, P., Puckner, C.D., Storb, R., Thomas, E.D., and Hansen, J.A. 1985. Marrow transplantation from related donors other than HLA-identical siblings. N. Eng. J. Med. 313:765.
23. Anasetti, C., Amos, D., Beatty, P.G., Appelbaum, F., Bensinger, W., Buckner, C.D., Clift, R., Doney, K., Martin, P.J., Micleson, E., Nisperos, B., O'Quigley, J., Ramberg, R., Sanders, J.E., Stewart, P., Storb, R., Sullivan, K.M., Witherspoon, R., Thomas, F.D., and Hansen, J.A. 1989. Effect of HLA compatibility on engraftment of bone marrow in patients with leukemia or lymphoma. N. Eng. J. Med. 320:197.
24. Freytes, C.O., Beatty, P.G.: Representation of Hispanics in the National Marrow Donor Program. Bone Marrow Transplantation 17:323, 1996.
25. Beatty, P.G., Anasetti, C., and Hansen, J.A. 1993. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: Effect of mismatching for one HLA locus. Blood 81: 249.
26. Hansen, J.A. 1996. Development of registries of HLA-typed volunteer marrow donors. Tissue Antigens 47:460.
27. Hansen, J.A., Petersdorf, E., Martin, P.J., and Anasetti, C. 1997. Hematopoietic stem cell transplants from unrelated donors. Immunological Reviews 157:141.
28. Kernan N. 1994. T-cell depletion for prevention of graft versus host disease, p. 124, in Forman S.J., Blume K.J., Thomas, E.D. (eds.), Bone Marrow Transplantation, Blackwell Scientific Publications, Oxford.
29. Martin, P.J., Hansen, J.A., Torok-Storb, B., Durnam, D., Przepiorka, D., O'Quigley, J., Sanders, J., Sullivan, K.M., Witherspoon, R.P., Deeg, H.J., Appelbaum, R.R., Stewart, P., Weiden, P., Doney, K., Buckner, C.D., Clift, R., Storb, R., and Thomas, E.D. 1988. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 3:445.
30. Marmont, A.M., Horowitz, M.M., Gale, R.P., Sobocinski, K., Ash, R.C., Van Bekkum, D.W., Champlin, R.E., Dicke, K.A., Goldman, I.M., Good, R.A., Herzig, R.H., Hong, R., Masaoka, T., Rimm, A.A., Ringden, O., Speck, B., Weiner, R.S., and Bortin, M.M. 1991. T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120.
31. Shizuru, J.A., Jerabek, L., Edwards, C.T., and Weismann, I.L. 1996. Transplantation of purified hematopoietic stem cells: Requirements for overcoming the barriers of allogeneic engraftment. Biology of Blood and Marrow Transplantation 2:3.
32. Shizuru, J.A., Jerabek, L., Edwards, C.T., and Weissman, I.L. 1996. Transplantation of purified hematopoietic stem cells: Requirements for overcoming the barriers of allogeneic engraftment. Biology of Blood and Marrow Transplantation 2:3.
33. Kaufman, C.L., Colson, Y.L., Wren, S.M., Watkins, S.L., Simmons, R.L., and Ildstad, S.T. 1994. Phenotypic characterization of a novel bone-marrow derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 84:2436.
34. Nilsson, S., Doone, M., Tiarks, C., Weier, H., and Quesenberry, P.J. 1997. Potential and distribution of transplanted hematopoietic stem cell in a nonablated mouse model. Blood 89:4013.
35. Vallera, D.A., and Blazar, B.R. 1989. T cell depletion for graft-versus-host disease prophylaxis. A perspective on engraftment in mice and humans. Transplantation 47:751.
36. Blazar, B.R., Filipovich, A.H., Kersey, J.H., Uckun, F.M., Ramsay, N.C., McGlave, P.B., and Vallera, D.A. 1987. T-cell depletion of donor marrow grafts: Effects on graft-versus-host disease and engraftment. New York, NY. Liss, p. 381.
37. Martin, P., Hansen, J., Buckner, C., Sanders, J., Deeg, H., Stewart, P., Appelbaum, F., Clift, R., Fefer, A., Witherspoon, R., Kennedy, M., Sullivan, K., Flournoy, N., Storb, R., and Thomas, E. 1985. Effects of in vitro depletion of T-cells in HLA-identical allogeneic marrow grafts. Blood 66:6641.
38. Storb, R., Deeg, H.J., Pepe, M., Appelbaum, F., Anasetti, C., Beatty, P., Bensinger, W., Berenson, R., Buckner, C.D., Clift, R., Doney, K., Longton, G., Hansen, J., Hill, R., Loughran, T., Jr., Martin, P., Singer, J., Sanders, J., Stewart, P., Sullivan, K., Witherspoon, R., and Thomas, E. 1989. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 73:1729.
39. Dunn, W.A., Raizada, M.K., Vogt, E.S., and Brown, E.A. 1994. Growth factor-induced neurite growth in primary neuronal cultures of dogs with neuronal ceroid lipofuscinosis. Int J Dev Neurosci 12:185.
40. Faust J.R., Rodman J.S., Daniel P.F., Dice J.F., and Bronson R.T. 1994. Two related proteolipids and dilichol-linked oligosaccharides accumulate in motor neuron degeneration mice (mnd/mnd), a model for neuronal ceroid lipofuscinosis. J. Biol. Chem. 269: 10150.
41. Lipman R.D., Donohue L.R., Hoppe P., and Bronson R.T. 1996. Evidence that lysosomal storage of proteolipids is a cell autonomous process in the motor neuron degeneration (mnd) mouse, a model of neuronal ceroid lipofuscinosis. Neurosci. Lett. 219:111.
42. Leong S.K., and Ling E.A. 1993. Origin and nature of ramified and ameboid microglia: A historical review and current concepts. Glia 6:39.
43. Unger E., Sung H., Manivel J.C., Cheggis M.L., Blazar B.R., and Krivit W. 1993. Male donor-derived cells i the brains of female sex-mismathced bone marrow transplant recipients: A y-chromo-some specific in-situ hybridization study. J. Neuropathaol. Exp. Neurol. 52:460.
44. Krivit W., Sung J.H., Shapiro E.G., Lockman L.A. 1995. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. [Review] [71 refs]. Cell Transplantation 4:385.
45. Kennedy D.W., and Abkowitz J.L. 1997. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood 90: 986.
46. Suzuki K. 1985. Genetic galctosylceramidase deficiency (globoid cell keukodystrophy, Krabbe disease) in different mammalian species. Neurochemical Pathology 3:53.
47. Suzuki K. 1995. The twitcher mouse: a model for Krabbe disease and for experimental therapies. [Review][63 refs]. Brain Pathology. 5:249.
48. Bradl M., and Linington C. 1996. Animal models of demyelination. [Review] [78 refs]. Brain Pathology 6:303.
49. Suzuki KSK. 1995. The twitcher mouse: A model for Krabbe disease and for experimental therapies. Brain Pathology 5:249.
50. Yeager A., Shinn C., Shinohara M., and Pardoll D. 1993. Hematopoietic cell transplantation in the twitcher mouse. Transplantation 56:185.
51. Neufeld E.F., and Muenzer J. 1995. The Mucopolysaccharidoses, p 2465, in Scirver CR, Beaudet AL, Sly WS, Valle D (eds.), The metabolic and molecular bases of inherited disease, McGraw-Hill, New York.
52. Simonaro C.M., Haskins M.E., Kunieda T., Evans S.M., Visser J.W., and Schuchman, E.H. 1997. Bone marrow transplantation in newborn rats with mucopolysaccharidosis type VI: biochemical, pathological, and clinical findings. Transplantation 63:1386.
53. Neufeld E.F., and Muenzer J. 1995. The Mucopolysaccharidoses, p. 2466, in Scirver CR, Beaudet AL, Sly WS, Valle D (eds.), The metabolic and molecular bases of inherited disease, McGraw-Hill, New York.
54. Gasper P.W., Thrall M.A., and Wenger D.A., et. al., 1984. Correction of feline arylsulfatase B deficiency (MPS VI) by bone marrow transplantation. Nature 312:467.
55. Wenger D.A., Gasper P.W., Thrall M.A., Dial S.M., LeCouteur R.A., and Hoover E.A. 1986. Bone marrow transplantation in the feline model of arylsulfatase B deficiency. Birth Defects 22:177.
56. Sands M.S., Barker J.E., Vogler C., Levy B., Gwynn B., Galvin N., Sly W.S., and Birkenmeier E. 1993. Treatment of murine mucopolysaccharidosis type VII by syngeneic BMT in neonates. J. Clin. Invest. 68:676.
57. Wolfe J.H., Sands M.S., Barker J.E., Gwynn B, Rowe L Vogler C., and Birkenmeier E. 1992. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature 360:749.
58. Marchael V., Naffakh N., Danos O., and Heard J.M. 1933. Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow stem cells. Blood 82:1358.
59. Sands M.S., Erway L.C., Vogler C., Sly W.S., and Birkenmeier E.H. 1995. Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII. Blood 86:2033.
60. Krivit W., Lockman L.A., Watkins P.A., Hirsch J., and Shapiro E.G. 1995. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. [Review] [23 refs]. Journal of Inherited Metabolic Disease 18:398.
61. Walkley S.U., Thrall M.A., Dobrenis K., Huang M., March P.A., Siegel D.A., and Wurzelmann S. 1994. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proceedings of the National Academy of Sciences of the United States of America 91:2970.
62. Vandevelde M., Fankhauser R., Bichsel P., Wiesmann U., and Herschkowitz N.: Hereditary neurovisceral mannosidosis associated with alpha-mannosidase deficiency in a family of Persian cats. Acta Neuropathologica 58:64, 1982
63. Cummings J.F., Wood P.A., de Lahunta A., Walkley S.U., and Le Boeuf L. 1988. The clinical and pathologic heterogeneity of feline alpha-mannnosidosis. Journal of Veterinary Internal Medicine 2: 163.
64. Shull R.M., Hastings N.E., Selcer R.R., Jones J.B., Smith J.R., Cullen W.C., and Constantopoulos G. 1987. Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system. Journal of Clinical Investigation 79:435.
65. Hoogerbrugge P.M., Brouwer O.F., Bordigoni P., Ringden O., Kapaun P., Ortega, J.J., O'Meara A., Cornu G., Souillet G., and Frappaz D. 1995. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation [see comments]. Lancet 345:1398.
66. Kidd D., Nelson J., Jone F., Dusoir H., Wallace I., McKinstry S., and Pearson-White S. 1998. Long-term stabilization after bone marrow transplantation in juvenile metachromatic leukodystrophy. Arch Neurol 55:98.
67. Joss V., Roger T.R., and Hugh-Jones K. 1982. A bone marrow transplant for metachromatic leukodystrophy. Exp. Hematology. 10:52.
68. Hoogerbrugger P.M., Brouwer O.F., and Fischer A. 1991. Bone marrow transplantation for metabolic diseases with severe neurological symptoms. Bone Marrow Transplant 7:71.
69. Hoogerbrugge P.M., Brouwer O.F., Bordigoni P., Ringden O., Kapaun P., Ortega, J.J., O'Meara A., Cornu G., Souillet G., and Frappaz D. 1995. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation [see comments]. Lancet 345:1398.
70. Krivit W. P.M., and Ayaz K. 1984. Bone marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). N. Engl. J. Med. 311:1606.
71. Resnick M., Krivit W., and Snover D.C. 1982. Pathology in the liver in mucopolysaccharidosis: Light and electron micorscopic assessment before and after bone marrow transplantation. Bone Marrow Transplantation 10:273.
72. Gasper P.W., Thrall M.A., and Wenger D.A., et. al. 1984. Correction of feline arylsulfatase B deficiency (MPS VI) by bone marrow transplantation. Nature 312:467.
73. Norrdin R.W., Moffat K.S., Thrall M.A., and Gasper P.W. 1993. Characterization of osteopenia in feline mucopolysaccharidosis VI and evaluation of bone marrow transplantation therapy. Bone 14: 361.
74. Wenger D.A., Gasper P.W., Thrall M.A., Dial S.M., LeCouteur R.A., and Hoover E.A. 1986. Bone marrow transplantation in the feline model of arylsulfatase B deficiency. Birth Defects 22:177.
75. McGovern M.M., Ludman M.D., and Short M.P., et. al. 1986. Bone marrow transplantation in Maroteaux-Lamy syndrome (MPS type 6): Status 40 months after BMT. Birth Defects 22:41.
76. Malm G., Ringden O., Winiarski J., Grondahl E., Uyebrant P., Eriksson U., Hakansson H., Skjeldal O., and Mansson J.E. 1996. Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation. Bone Marrow Transplantation 17:1003.
77. Navarro C., Dominguez C., Fernandez J.M., Fachal C., and Alvarez M. 1995. Case report: four-year follow-up of bone-marrow transplantation in late juvenile metachromatic leukodystrophy. Journal of Inherited Metabolic Disease 18:157.
78. Yazaki M., Ohno T., Matsubayashi T., Yamada K., Osaka Y., Yamamori K., Ishikawa T., Wada Y., and Sakuraba H. 1995. Detection of donor lymphocytes in the cerebrospinal fluid of a patient with metachromatic leukodystrophy following bone marrow transplantation. Bone Marrow Transplantation 15:137.
79. Nagai T., Kaneko T., Shichijou H., Karato T., Maruyama A., and Tsuchiya Y. 1993. Bone marrow transplantation for late infantile metachromatic leukodystrophy: pathogenic investigation for graft rejection. Acta Paediatrica Japonica 35:404.
80. Bambach B.J., Moser H.W., Blakemore K., Corson V.L., Griffin C.A., Noga S.J., Perlman E.J., Zuckerman R., Wenger D.A., and Jones R. J. 1997. Engraftment following in utero bone marrow transplantation for globoid cell leukodystrophy. Bone Marrow Transplantation 19:399.
81. Staba M.J., Goldman S., Johnson F.L., and Huttenlocher P.R. 1997. Allogeneic bone marrow transplantation for Alexander's disease. Bone Marrow Transplantation 20:247.
82. Di Francesco C., Cracco C., Tomain R., Picci L., Ventura L., Zacchello E., Di Natale P., Anson D.S., and Howood J.J. 1997. In vitro correction of iduronate-2-sulfatase deficiency by adenovirus-mediated transfer. Gene. Therapy 4:442.
83. Krivit W., Shapiro E.G., Peters C.P., Wagner J.E., Cornu G., Kurtzberg J., Wenger D.A., Kolodny E.G., Vanier M.T., Loes D.J., Dusenbery K., and Lockman L.A. 1998. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N. Eng. J. Med. 330:1119.
84. Hoogerbrugge P.M., Brouwer O.F., Bordigoni P., Ringden O., Kapaun P., Ortega, J.J., O'Meara A., Cornu G., Souillet G., and Frappaz D. 1995. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation [see comments]. Lancet 345:1398.
85. Suzuki K., and Taniike M. 1995. Murine model of genetic demyelinating disease: the twitcher mouse. [Review] [61 refs]. Microscopy Research & Technique 32:204.
86. Vassal G., Fischer A., Challine D., Boland I., Ledheist F., Lemerie S., Vilmer E., Rahimy C., Souillet G., Gluckman E., Michel G., Deroussent A., and Gouyette A. 1993. Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease. Blood 82:1030.
87. Vassal G., Deroussent A., Challien D., Harment O., Koscielny S., Valteau-Couanet D., Lemerie J., and Gouyette A. 1992. Is 600 mg/kg2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 79:2475.
88. Grochow L.B., Piantadosi S., Santos G., and Jones R. 1992. Busulfan doses adjustment decreases the risk of veno-occulsive disease in patients undergoing bone marrow transplantation. Proc. American Assoc. Cancer Res. 33:200.
89. Nash R.A., Seidel K., Storb R., Slichter S., Schuening F.G., Appelbaum F.R., Becker A.B., Bolles L., Deeg H.J., and Graham T. 1995. Effects of rhIL-11 on normal dogs and after sublethal radiation. Experimental Hematology 23:389.
90. Cobbold S.P., Martin G., Qin S., and Waldmann H. 1986. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 323:164.